A single, global, randomized, double-blind, controlled Phase 3 pivotal trial of a 90-day prophylaxis regimen of rezafungin in patients undergoing allogeneic bone marrow transplant
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Rezafungin (Primary) ; Azoles; Sulfamethoxazole; Trimethoprim
- Indications Aspergillosis; Candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms ReSPECT Prophylaxis
- Sponsors Cidara Therapeutics
- 27 Nov 2018 According to a Cidara Therapeutics media release, the company plans to start this study in the first quarter of 2019.
- 19 Mar 2018 According to a Cidara Therapeutics media release, the company expected to produce an interim futility read-out in 2019.
- 16 Nov 2017 New trial record